Pfizer and BioNTech Ink Deal with U.S. Government for Big Coronavirus Vaccine Purchase – Motley Fool

Share this article!

Washington will pay the partners $1.95 billion upon shipment of those 100 million dosages. The agreement likewise gives the government the option to acquire 500 million additional doses. Keep in mind that on Monday, the 2 companies revealed a similar (albeit smaller sized) handle the U.K. federal government.

As the worldwide efforts to discover a vaccine heat up, the next couple of months will be vital for Pfizer and BioNtech.

Even more, the healthcare companies prepare to start a stage 2b/3 clinical trial by the end of July, pending regulatory approval. That research study is expected to enroll up to 30,000 healthy individuals, and will check the safety and efficacy of the chosen vaccine prospect. It is also worth noting that the Food and Drug Administration has actually given fast-track designation to 2 of the candidates in the bnt162b2, program and bnt162b1.

Pfizer (NYSE: PFE) and BioNtech (NASDAQ: BNTX) are collectively establishing 4 mRNA-based vaccine prospects for the SARS-CoV-2 coronavirus. And on Wednesday early morning, the companies revealed that they had actually signed a deal with the U.S. governments Health and Human Services (HHS) and Defense departments to supply them with a minimum of 100 million dosages of whichever prospect makes regulatory approval or emergency situation utilize permission– presuming one does.

Image source: Getty Images.

Pfizer and BioNtech are currently running a stage 1/2 medical trial for the coronavirus vaccine candidates in the BNT162 program, and they recently launched positive study information for BNT162b1– the most sophisticated of the bunch.

Pfizer and BioNtech arent the only ones attempting to develop mRNA-based COVID-19 vaccines– Moderna (NASDAQ: MRNA) is too, and its likewise well advanced in the development process. That biotech company prepares to begin a stage 3 clinical trial on July 27 for its lead candidate, mRNA-1273. The pivotal research study will enlist about 30,000 individuals, and its primary endpoint will be “the prevention of symptomatic COVID-19 illness.”